Kindergarten vaccination rates fall as exemptions rise
The data, posted to the Centers for Disease Control and Prevention website Thursday, showed vaccination coverage among kindergartners during the 2024 to 2025 school year decreased for all reported vaccines from the year before.
According to the data, about 92.1% kindergartners got the diphtheria, tetanus and acellular pertussis vaccine (DTaP), and 92.5% received the measles, mumps and rubella vaccine (MMR) and polio vaccine — all down slightly from the previous school year.
These decreases come as the U.S. has recorded the most measles cases in more than 30 years. A large share of the infections were connected to a West Texas outbreak primarily affecting children and teenagers, nearly all of whom were unvaccinated or have an unknown vaccination status.
Experts say outbreaks like these are more likely when vaccination rates drop — and rates have already fallen below the 95% needed for herd immunity.
Exemptions among U.S. kindergartners also rose to an all-time high during the 2024 to 2025 school year, the data showed, increasing to 3.6% from 3.3% the year before.
Exemptions increased in 36 states and Washington, D.C., with 17 states reporting exemptions exceeding 5%, the CDC added.
Speaking on "CBS Mornings" earlier this year about the measles outbreak, Dr. Céline Gounder, CBS News medical contributor and editor-at-large for public health at KFF Health News, expressed worry over exemption increases across the country.
"We're really seeing a lot of exemptions [and] concerns about vaccination that are not warranted," she said, adding, for most people, the MMR vaccine will protect you for life against measles, one of the most contagious infectious diseases. Doctors and public health officials say the vaccine, which has been used for decades, is safe and highly effective.
Arkansas officials reveal new details about Devil's Den murders of husband and wife
New shocking jobs report as Trump's tariffs roll out
Autistic researcher finds new path as DEI programs face cuts
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
2 hours ago
- Associated Press
Luum Announces Corewell as Best Gut Health Supplement for IBS and Bloating Relief
Luum's Corewell, a groundbreaking three-phase gut restoration system, has been awarded Best Gut Health Supplement for IBS and Bloating Relief in the US for 2025. United States, August 4, 2025 -- Transforming Gut Health: Luum's Corewell Recognized for IBS and Bloating Relief Luum, a pioneering gut health company, has recently been awarded Best Gut Health Supplement for IBS and Bloating Relief in the US for 2025 by Best of Best Review. The recognition highlights Corewell, Luum's innovative three-phase gut restoration system designed to address the root causes of digestive discomfort, including IBS, bloating, and other chronic gut issues. Combining modern science with ancient wisdom, Luum's Corewell has proven to be a transformative solution in the wellness space, providing lasting relief from digestive struggles. The Power of Corewell: A Three-Phase System for Lasting Relief The award comes as no surprise to those who have experienced the effectiveness of Luum's Corewell. This patent-pending product takes a unique, multi-phase approach to gut health, addressing the root causes of digestive issues rather than simply masking the symptoms. Corewell is structured around three distinct phases: Cleanse, Repair, and Rebalance. This carefully designed sequence is what sets Corewell apart from other gut health solutions, which typically focus on a single aspect of digestion. By ensuring that each phase works in synergy with the next, Corewell's three-step system guarantees a holistic approach to gut restoration. A Personal Journey Leading to Innovation The story behind Corewell's creation is deeply personal. Founder Mohammad Bazeed spent 15 years battling chronic digestive issues, trying countless treatments without lasting success. 'I tried everything – from diets to prescriptions – but nothing addressed the root causes,' says Bazeed. His frustration drove him to research the importance of cleansing the gut before attempting to rebuild it, which led to the creation of Corewell. The result is a solution that not only heals the gut but also ensures the gut is in the optimal condition for absorbing the beneficial ingredients Corewell delivers. This personal journey has inspired Luum's commitment to offering science-backed, natural solutions. 'We believe that gut health isn't just about symptom management; it's about addressing the underlying causes in the right sequence,' Bazeed shares. This dedication to effective, long-term gut restoration has solidified Corewell's position as a leading product in the digestive wellness space. Groundbreaking Science Behind Corewell Corewell is powered by 16 clinically researched ingredients, each chosen based on their proven efficacy. These ingredients, such as Sweet Wormwood, known for its pathogen-clearing properties, and L-Glutamine, which supports gut lining integrity, have been included due to decades of peer-reviewed studies supporting their effectiveness. Luum's commitment to innovation is reflected in the product's delayed-release capsule technology, which ensures that the ingredients reach the gut intact, avoiding degradation by stomach acid. This approach maximizes absorption in the small intestine, where nutrient absorption is most critical. 'We've taken what science and tradition have proven works and optimized it for the modern gut,' says Bazeed. The result is a system that works with the body's natural healing processes, providing not just symptom relief but true restoration. Luum's Award-Winning Solution: Corewell Luum's Corewell is more than just a supplement; it's a comprehensive gut restoration system that eliminates the need for multiple products. While traditional supplements address individual aspects of digestion, Corewell's multi-phase approach simplifies the process and reduces costs for consumers. The Best Gut Health Supplement for IBS and Bloating Relief recognition underscores Corewell's holistic benefits. Unlike other products, which may only provide short-term relief, Corewell offers lasting digestive wellness by supporting each phase of gut restoration. Luum's transparency is also a key factor in the company's success. All ingredients used in Corewell are third-party tested for purity and potency, ensuring that customers receive the highest quality product. Manufactured in FDA-registered, GMP-certified facilities in the United States, Corewell meets the highest industry standards for quality and safety. Customer Stories: Real Results, Real Impact The effectiveness of Corewell has not gone unnoticed by its users. Customers like Sarah M., a 38-year-old marketing director from San Francisco, have shared their positive experiences after using Corewell. 'I was so bloated every night I couldn't button my jeans. Week one on Corewell and I noticed a difference. By week 4, I was eating normally again without the constant worry. The brain fog clearing was an unexpected bonus.' Similarly, Michael R., a 45-year-old software engineer from Austin, describes his journey: 'I spent thousands trying to fix my gut. What got me about Corewell was the three-phase system – it actually made sense. No crazy detox reactions, just gradual improvement. Six weeks in and my energy is back. Worth every penny.' These personal success stories reflect the growing impact Corewell has had on those suffering from chronic digestive issues, reinforcing its status as a breakthrough solution for gut health. About Luum Founded in 2025 by Mohammad Bazeed, Luum is a groundbreaking gut health company dedicated to combining ancient wellness practices with modern scientific research. The company's flagship product, Corewell, is a three-phase system designed to restore gut health through targeted cleansing, repair, and rebalancing. Manufactured in FDA-registered, GMP-certified facilities in the United States, Luum offers science-backed, natural solutions for digestive wellness. Media Contact Mohammad Bazeed Founder, Luum Email: [email protected] Website: Contact Info: Name: Mohammad Bazeed Email: Send Email Organization: Luum Website: Release ID: 89166349 If there are any deficiencies, discrepancies, or concerns regarding the information presented in this press release, we kindly request that you promptly inform us by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team is committed to addressing any identified issues within 8 hours to guarantee the delivery of accurate and reliable content to our esteemed readers.
Yahoo
2 hours ago
- Yahoo
World-first vaccine rolled out across England amid record levels of infection
England has launched a world-first gonorrhoea vaccination programme, aimed at curbing soaring infection rates and tackling the growing threat of antibiotic-resistant strains. The initiative comes after cases of the sexually transmitted infection (STI) in England reached a record 85,000 in 2023, the highest since records began in 1918. Available free of charge from Monday at sexual health clinics, the jab is being offered to those at highest risk. This includes gay and bisexual men with a recent history of multiple sexual partners or a bacterial STI. The vaccine, an existing jab known as 4CMenB, is currently used to protect against meningococcal B disease, which can cause meningitis and sepsis. It is used in the routine childhood programme and given to babies at eight weeks, 16 weeks and one year. Officials anticipate the programme will save the NHS £7.9 million over the next decade. The programme could prevent up to 100,000 cases of gonorrhoea, according to doctors. The STI disproportionately impacts specific communities, such as those in deprived areas, people of black Caribbean ethnicity, and gay, bisexual and other men who have sex with men, according to the Joint Committee on Vaccination and Immunisation (JCVI). Patients getting the gonorrhoea vaccine will also be offered jabs for mpox, human papillomavirus (HPV), and hepatitis A and B at their appointment. 'Rolling out this world-leading gonorrhoea vaccination programme in sexual health clinics in England represents a major breakthrough in preventing an infection that has reached record levels,' Ashley Dalton, the minister for public health and prevention, said. 'This government's world-first vaccination programme will help turn the tide on infections, as well as tackling head-on the growing threat of antibiotic resistance. 'I strongly encourage anyone who is eligible to come forward for vaccination, to protect not only yourselves but also your sexual partners.'
Medscape
3 hours ago
- Medscape
New Lyme Blood Test Bests Standard Diagnostics
A new blood test for Lyme disease outperforms standard diagnostic testing across all stages of the disease, according to new data presented at the 2025 Association for Diagnostics and Laboratory Medicine annual meeting in Chicago. The test, which pairs a multiplexed assay with a machine learning algorithm, showed over 90% accuracy in diagnosing Lyme disease in 308 human serum samples. The CDC estimates that about 476,000 individuals may be diagnosed and treated for Lyme disease each year in the US. The tick-borne disease, caused primarily by infection with Borrelia burgdorferi , is most treatable in the first few weeks of infection, but diagnosis during this early stage poses a challenge to clinicians. Barriers to Early Diagnosis The most common sign of early infection is a skin rash called erythema migrans (EM) that often occurs at the site of the tick bite. While a bull-eye-shaped rash is telltale sign of Lyme disease, this type of EM is actually not a common presentation, said Liz Horn, PhD, MBI, principal investigator of the Lyme Disease Biobank, a biorepository of samples from people with Lyme disease, headquartered in Portland, Oregon. She was not involved with the work. EMs can present in different forms, and about 30% of people with Lyme disease do not develop a rash. 'If you don't have a rash, you have to rely on serologic tests,' Horn said, which are notoriously insensitive in early disease, as antibodies can take weeks to develop. The CDC currently recommends a two-test format. Standard two-tier testing (STTT) involves an enzyme immunoassay as the first step, which, if positive or indeterminate, is followed by a Western Blot. In the first few weeks of disease, antibody levels can be too low to detect, leading to false negatives. In a recent study led by Horn using samples from individuals with signs and symptoms of early Lyme disease who were enrolled in the Lyme Disease Biobank, just 34% of patients presenting with EM > 5 cm tested positive on serologic tests. Among patients without EM, only 16% had positive results, and among those with EM ≤ 5 cm, the positivity rate dropped to just 5%. 'If we could get a serology test that works better in early disease, that could have great benefits for both patients and providers,' Horn said. Pairing AI With a Multiassay This new blood test, called LymeSeek, works differently by detecting 10 different antigens simultaneously. An algorithm developed using deep learning 'sorts through all of the responses,' explained Holly Ahern, MS, MT, the chief scientific officer of ACES Diagnostics, the company developing LymeSeek, in Paradise Valley, Arizona. 'That is what gives the test its very high sensitivity and specificity,' she said. Ahern is also an associate professor of microbiology at State University of New York at Adirondack (SUNY Adirondack) in Queensbury, New York. To validate the test, developers analyzed the human serum samples of 150 control individuals and 158 Lyme disease cases, across all phases of Lyme disease. Samples were provided by the Lyme Disease Biobank, the CDC, and the Johns Hopkins University Lyme Disease Research Center in Baltimore. The control samples were from patients in endemic and nonendemic areas and included individuals with non-Lyme look-like diseases, like mononucleosis and rheumatoid arthritis. The test correctly classified 281 samples as Lyme cases or control individuals, resulting in a test sensitivity of 91.7% and a specificity of 90.7%. In an additional analysis, the ACES diagnostics team also compared LymeSeek to STTT using samples from the Johns Hopkins Lyme Disease Research Center. In very early stages of disease (0-72 hours after appearance of an EM rash), LymeSeek diagnosed 100% of Lyme cases, whereas standard testing identified only 37% of cases. In samples taken 3-4 weeks after EM appearance, LymeSeek's results remained consistent, and standard testing identified 76% of cases. 'The observed seroconversion indicates the enrolled patients did have Lyme disease and is a confirmation that the test result given by LymeSeek is a true positive test result,' Ahern added. In patients with post-treatment Lyme disease (6 months or more after infection), LymeSeek identified 97% of cases, whereas standard testing identified less than half (46%). 'With this one single test, we can detect [Lyme] in the early stages, but we can also detect it across all stages of the disease' Ahern said, which includes through 1 year from first Lyme diagnosis. ACES Diagnostics is now working to develop a clinical trial plan with the FDA. The test has received a De Novo classification, meaning it's being evaluated on its own merits rather than compared to the current standard diagnostics. 'We're not just showing that we are as good as two-tier serology because what's the point of being as good as a test that really isn't very good?' Ahern said.
